Plus Therapeutics Announces Reverse Stock Split

Core Viewpoint - Plus Therapeutics, Inc. has announced a reverse stock split at a ratio of 1-for-25 to comply with Nasdaq's minimum bid price requirement of $1.00 for continued listing [1][2]. Group 1: Reverse Stock Split Details - The reverse stock split will take effect at 12:01 a.m. Eastern Time on April 2, 2026, reducing the outstanding common stock from approximately 171,550,698 shares to about 6,862,027 shares [1][3]. - Every 25 shares of Plus Therapeutics common stock will be combined into one share, with no change to the par value of $0.001 per share [3]. - Holders of fractional shares will receive a cash payment instead of fractional shares, and the shares underlying the Company's outstanding equity awards and warrants will also be adjusted accordingly [3]. Group 2: Stockholder Instructions - The Company has retained Broadridge Financial Services, Inc. as the exchange agent for the reverse stock split, providing instructions for stockholders with shares in certificate form [4]. - Stockholders holding shares in book-entry form or brokerage accounts will see the impact of the reverse stock split reflected in their accounts without needing to take action [4]. Group 3: Company Overview - Plus Therapeutics, Inc. is a clinical-stage pharmaceutical company focused on developing targeted radiotherapeutics for central nervous system cancers, aiming to enhance clinical outcomes [5]. - The Company is advancing a pipeline of product candidates, particularly in leptomeningeal metastases and recurrent glioblastoma, supported by strategic partnerships for development and manufacturing [5].